Skip to Content


  • Open Source Software Tool Skyline Reaches Key Agreement with Mass Spectrometer Vendors

    The full proteomics analysis of a small tumor sample (similar in mass to a few grains of rice) produces well over 500 megabytes of unprocessed "raw" data when analyzed on a mass spectrometer (MS). Thus, for every proteomics experiment there is a vast amount of raw data that must be analyzed and interrogated in order to extract biological information.

  • CPTC expand scope of Reagents and Resources Core

    Whether in determining if a women is pregnant or not by measuring human chorionic gonadotropin or determining whether someone is HIV positive, antibodies and other affinity reagents play a key role both in diagnostic decision making and advancing the research field.

  • Advances in understanding regulatory science takes center stage

    Regulatory advances in proteomics will be taking center stage at a Symposia scheduled to occur at the 2011 American Association for Clinical Chemistry (AACC) Annual Meeting. The symposium entitled "Enabling Translational Proteomics with NCI's Clinical Proteomic Technologies for Cancer" is scheduled for July 25, 2011 at AACC's annual Meeting.

  • NCI seeks to engage the creativity of the research community

    Is there a specific advance that must be made in order to advance our understanding of cancer and cancer control?

  • NCI, NHLBI, FDA, AACC, and CMS Collaborate in Advancing Proteomics Regulatory Science

    Despite great strides in proteomics and the growing number of articles citing the discovery of potential biomarkers, the actual rate of introduction of Food and Drug Administration (FDA) approved protein analytes has been relatively unchanged over the past 10 years. One of reasons for the lack of new protein-based biomarkers approved has been a lack of information and understanding by the proteomics research community to the regulatory process used by the FDA.

  • 1